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Lipid accumulationChronic kidney disease (CKD) is associated with increased risks of cardiovascular morbidity and mortality. Car-
diac remodeling including myocardial ﬁbrosis and hypertrophy is frequently observed in CKD patients. In this
study, we investigate the mechanism involved in cardiac hypertrophy associated with CKD using a rat model,
by morphological and chemical component changes of the hypertrophic and non-hypertrophic hearts.
Sprague–Dawley rats were 4/5 nephrectomized (Nx) at 11 weeks of age and assigned to no treatment and treat-
mentwith AST-120,whichwas reported to affect the cardiac damage, at 18 weeks of age. At 26 weeks of age, the
rats were euthanized under anesthesia, and biochemical tests as well as analysis of cardiac condition were per-
formed by histological and spectrophotometric methods. Cardiac hypertrophy and CKD were observed in 4/5
Nx rats even though vascular calciﬁcation and myocardial ﬁbrosis were not detected. The increasing myocardial
protein was conﬁrmed in hypertrophic hearts by infrared spectroscopy. The absorption of amide I and other pro-
tein bands in hypertrophic hearts increased at the same position as in normal cardiac absorption. Infrared spectra
also showed that lipid accumulationwas also detected in hypertrophic heart. Conversely, the absorptions of pro-
teinwere obviously reduced in themyocardium of non-hypertrophic heart with CKD compared to that of hyper-
trophic heart. The lipid associated absorption was also decreased in non-hypertrophic heart. Our results suggest
that cardiac remodeling associated with relatively early-stage CKD may be suppressed by reducing increased
myocardial protein and ameliorating cardiac lipid load.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Patientswith chronic kidney disease (CKD) generally have increased
risks of complications including accelerated cardiovascular disease
compared to the general population [1]. Cardiac mortality is the main
cause of death and marked cardiac remodeling is frequently observed
in CKD patients [2]. Molecular, cellular and interstitial changes are re-
ported to manifest clinically as changes in size, shape and function of
the heart, resulting from cardiac load or injury [3]. Cardiac remodeling
is now recognized as an important aspect of cardiovascular disease
progression.
Cardiac hypertrophy is the primary mechanism in cardiac remodel-
ing, and is one of the compensatory actions by a large number of phys-
iological and pathological conditions. When hypertrophy occurs, the
tension generated by the contraction of the myocardium is increased,
and the contractile force of the heart increased. Cardiac hypertrophy
has, at the beginning, beneﬁcial effects in terms of muscular economy,logy Center, Kureha Corporation,
an. Tel.: +81 3 3362 7421; fax:
a).normalizing wall stress [4]. However, as hypertrophy progresses, myo-
cardial damage is caused by an imbalance of contraction or excessive
stretching. Chronic hypertrophy is reported to be associated with a
signiﬁcant increase in the risk of heart failure, dilated cardiomyopathy,
ischemic heart disease, and sudden death, leading to increased cardio-
vascular mortality [5–9]. Fibrosis is reported to manifest on various
morphologically distinct forms [10], andmyocardial ﬁbrosis is often ob-
served in hypertrophic heart. In CKDmodel rats, interstitial ﬁbrosis was
reduced by treatment with a calcimimetic, despite no effect on cardiac
hypertrophy [11]. Myocardial ﬁbrosis is probably a consequence of
hypertrophy. Thus, it is important to prevent the compensated cardiac
hypertrophy with CKD, which is the previous stage of decompensated
hypertrophy leading to heart failure. Hypertension is often noticed as
a cause of cardiac hypertrophy [12]. Inorganic phosphorus (Pi), parathy-
roid hormone (PTH), ﬁbroblast growth factor 23 (FGF23) and anemia
are also regarded recently as candidates associated with cardiac hyper-
trophy with CKD [13–16]. Various studies have been conducted, but
many questions remain unanswered.
It is necessary to conﬁrm the signiﬁcant changes associated with
cardiac pathologies to prevent hypertrophy. Cardiac hypertrophy is
more likely to begin at early-stage of renal insufﬁciency, and only the
staining methods have limits to examine the cardiac changes due to
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infrared (FTIR) spectroscopy have been used for over half a century for
structural analysis in biophysics and biochemistry. Recent technological
developments in FTIR spectroscopy have enabled the possibility for ap-
plications in histopathologic imaging for diagnosis and research of dis-
ease. FTIR microspectroscopy provides structural information as well
as relative quantiﬁcation of lipids, proteins, carbohydrates and a variety
of phosphorylated biomolecules within biological samples such as cell
or tissue [17].
The present study aimed to investigate the mechanism involved in
cardiac hypertrophy associatedwith CKD using a ratmodel, bymorpho-
logical and chemical component changes of the hypertrophic heart. In
addition, we considered the suppression mechanism of hypertrophy,
by using a CKD model rat treated with AST-120 (Kremezin®; Kureha
Corporation, Tokyo, Japan) [18,19] that has been reported to prevent
the progression of cardiac damage in CKD [20–22].
2. Material and methods
2.1. Surgical model for CKD
Nine-week-old male Sprague–Dawley rats were purchased from
Japan SLC, Inc. (Hamamatsu, Japan). At 10 weeks of age (260–280 g in
weight), rats were anesthetized with sodium pentobarbital (5 mg/100
g body weight) and the left kidney was resected at top and bottom
slant 45° from the center to standardize the size of residual renal tissue
in CKD model rats. One week later, right nephrectomy was performed
leaving approximately 1/5 of the total renal mass. Six age-matched
rats were sham-operated as controls (sham-control group). Seven
weeks after nephrectomy, nephrectomized rats were divided into
three groups. One groupwas not treated with AST-120 (non-AST-treat-
ed group) and two groupswere treatedwith different doses of AST-120.
One AST-120-treated groupwas fed a diet containing 4% AST-120 (AST-
low group) and the other group was fed a diet containing 8% AST-120
(AST-high group). Mean amount of AST-120 dose was calculated from
mean food consumption in a day and the result of sample analysis
(CE-2 including 25% protein and 5% lipid; CLEA Japan Inc., Tokyo,
Japan). Blood samples during experimental period were collected
from the jugular vein under anesthesia. At 26 weeks of age, the rats
were euthanized under anesthesia after 24-h urine samples were col-
lected usingmetabolic cages. Blood sampleswere collected from the ab-
dominal aorta for biochemical measurements, and the hearts and
thoracic aortas were removed for weight measurement and the other
analyses. All animal care and procedures were approved by the Animal
Care and Use Committee of Kureha Corporation.
2.2. Evaluation of cardiac hypertrophy
The weight and cross-sectional area of the heart were measured
to evaluate cardiac hypertrophy. Four-μm transverse sections of the
heart at the equatorial plane were cut. The section just below the
right atrium provides the largest cut surfaces. The cross-sectional
areas of hematoxylin and eosin (HE)-stained sections were ana-
lyzed using a Leica QwinV3 System (Leica Microsystems, Solms,
Germany). Cross-sectional areas of the heart in study groups were
expressed as ratios relative to the area in sham-control group.
2.3. Biochemical analysis
After centrifugation, serum and urine samples were stored at 4 °C
until analysis. Serum Cr, BUN, total cholesterol (T-Cho), triglycerides
(TG) and Pi levels, and urinary Cr and protein levels were measured
using a Unicel DxC 600 Clinical System (Beckman Coulter. Inc., CA,
USA). Hemoglobin level in blood was measured using a multichannel
blood cell counter (XT-2000i; Sysmex Corporation, Hyogo, Japan).
Serum levels of PTH, FGF23 and heart-type fatty acid binding protein(H-FABP) and urinary 8-hydroxydeoxyguanosine (8-OHdG) level
were measured using enzyme-linked immunosorbent assay kits (PTH:
Rat Intact PTH ELISA Kit; Immutopics, CA, USA. FGF23: FGF-23 ELISA
Kit; Kainos Laboratories, Tokyo, Japan. H-FABP: Rat H-FABP ELISA Kit;
Life Diagnostics, Inc., PA, USA, 8-OHdG:New8-OHdGCheck; Japan Insti-
tute for the Control of Aging, Shizuoka, Japan). Serum levels of colon-
derived uremic toxins were determined by liquid chromatography
with tandem mass spectrometry (LC/ESI-MS/MS) [23].
2.4. Blood pressure measurements
Systolic blood pressure (SBP), diastolic blood pressure (DBP) and
heart rate (HR) were measured in conscious, restrained rats by tail-
cuff plethysmography (Model BP-98A; Softron, Tokyo, Japan). To reduce
the possibility of stress artifacts, the rat was allowed to acclimatize suf-
ﬁciently and the mean of ﬁve measurements was recorded.
2.5. Histological staining
Heart tissues were ﬁxed in 10% formalin, dehydrated at room tem-
perature through an ethanol series and embedded in parafﬁn. Four-
μm serial sections were cut from the parafﬁn blocks. Sections were
stained with HE for routine histology and Masson's trichrome (MT)
for interstitial ﬁbrosis.
The HE-stained sections of the thoracic aortas were prepared in the
same manner.
2.6. Spectrophotometric analysis
Four-μmsections used in this studywere the adjacent sections of the
HE-stained sectionsused for evaluating cross-sectional area of theheart.
The sections were mounted on barium ﬂuoride disks for spectrophoto-
metric analysis. FTIR images of a section of the heart were acquired at
25 μm (partial tissue sections) or 50 μm (whole tissue sections) pixel
resolution and 8 cm−1 spectral resolution with two co-added
scans using a Spotlight 400 spectrometer (PerkinElmer, MA, USA). The
mean spectrum of each group was composed of the mean spectra of
1500 × 1500 μm area of myocardium in each rat. Background spectra
were collected from the same barium ﬂuoride window under identical
condition.
Barium ﬂuoride disks of the thoracic aortas were prepared in the
samemanner. FTIR image of a section of the thoracic aorta was acquired
at 6.25 μm pixel resolution and 4 cm−1 spectral resolutionwith two co-
added scans.
2.7. Statistical analysis
Data are expressed as means ± SD. One-way analysis of variance
followed by Student's t-test (between non-AST-treated and sham-
control group) and Tukey–Kramer post-hoc test (among CKD model
groups or four groups) was used to compare inter-group differences.
Relationships between variables were assessed using univariate linear
regression analysis. A P value less than 0.05 was considered statistically
signiﬁcant.
3. Results
3.1. Cardiac hypertrophy in CKD rats
The physical characteristics and biochemical data of the CKD model
and sham-control rats at 26 weeks are shown in Table 1. Body weights
were similar in two groups. SBP, DBP andHRwere signiﬁcantly elevated
in non-AST-treated rats compared to sham-controls. As for kidney
function, creatinine clearance (CCr) was signiﬁcantly lower and serum
Cr, BUN and urinary protein were signiﬁcantly elevated in the
groups of non-AST-treated rats (n = 7) compared to sham-control
Table 1
Animal characteristics in chronic kidney disease model and sham-control rats at 26 weeks of age.
Non-AST-treated (chronic kidney disease, n = 7) Sham-control (n = 6)
Body weight, g 532.7 ± 24.7 538.9 ± 30.6
Systolic blood pressure, mm Hg 174.5 ± 32.8** 115.5 ± 7.9
Diastolic blood pressure, mm Hg 118.0 ± 19.4** 88.1 ± 4.2
Heart rate, bpm 323.1 ± 26.5** 274.6 ± 15.2
Hemoglobin, g/dL 13.4 ± 0.9** 16.1 ± 0.3
Creatinine clearance (CCr), mL/min 1.28 ± 0.53** 4.48 ± 0.42
Serum creatinine, mg/dL 1.34 ± 0.65** 0.29 ± 0.03
Blood urea nitrogen, mg/dL 72.3 ± 17.5** 20.9 ± 0.6
Urinary protein, mg/day 229.3 ± 118.0** 12.4 ± 3.2
Indoxyl sulfate, mg/dL 0.60 ± 0.24** 0.10 ± 0.03
p-Cresyl sulfate, μg/dL 6.43 ± 3.60** 1.33 ± 0.52
Hippuric acid, mg/dL 0.78 ± 0.33** 0.17 ± 0.06
Inorganic phosphorus, mg/dL 6.26 ± 0.79 5.85 ± 0.34
Parathyroid hormone, pg/mL 2077.7 ± 1942.6 379.2 ± 229.2
Fibroblast growth factor 23, pg/mL 2348.7 ± 2877.7 315.6 ± 43.4
Total cholesterol, mg/dL 119.9 ± 27.8** 47.0 ± 6.4
Triglycerides, mg/dL 254.0 ± 65.2 313.0 ± 77.4
Heart-type fatty acid binding protein, ng/mL 0.87 ± 0.31** 0.25 ± 0.13
8-OHdG (ng/day) corrected by CCr (mL/min) 216.8 ± 136.2** 23.4 ± 10.1
8-OHdG; 8-hydroxydeoxyguanosine, **P b 0.01; vs. Sham-control.
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sulfate (IS), p-cresyl sulfate (PCS) and hippuric acid (HA)] were elevated
signiﬁcantly in non-AST-treated group compared to sham-control group.
Mineral metabolic parameters (serum Pi, PTH and FGF23) did not differ
signiﬁcantly between two groups. In serum lipids and parameter
associated with lipid, serum T-Cho and H-FABP levels were signiﬁcantly
elevated in non-AST-treated compared to sham-control group, but
serum TG level did not differ between the two groups. Hemoglobin
level was signiﬁcantly lower in non-AST-treated rats compared to
sham-controls. Oxidative stress, which was expressed as the CCr-
corrected level of urinary 8-OHdG [24], signiﬁcantly increased in non-
AST-treated group compared to sham-control group.
Cardiac hypertrophy was deﬁned as increases in heart weight and
ventricular wall thickness. Heart weight was signiﬁcantly greater in
non-AST-treated (1.7-fold vs. sham-control) group compared to
sham-control (Fig. 1A). Cross-sectional area of the heart was measured
to evaluate the ventricular wall thickness. Cardiac cross-sectional area
was signiﬁcantly greater in non-AST-treated (1.4-fold vs. sham-
control) group compared to sham-control group (Fig. 1B).
Fig. 1C shows the HE and MT stained sections of the central portion
of the myocardium of representative rats in two groups. In HE-stainedFig. 1.Cardiac hypertrophy in chronic kidney disease (CKD)model rats. (A)Heartweight in CKD
Sham, sham-operated rats (n=6). Heartweight is expressed as heartweight (g) per 100 g body
sham-operated rats. No-AST (n= 7); Sham (n = 6). Relative cross-sectional area is expressed
(HE, upper) and Masson's trichrome staining (MT, lower) (magniﬁcation × 40) of the central psections, the width of myocardial ﬁbers increased clearly in non-AST-
treated (heart weight: 1.7-fold vs. sham-control) rats compared to
sham-control rat. In MT-stained sections, myocardial ﬁbrosis was not
obvious in representative CKDmodel rat compared to sham-control rat.
3.2. Chemical changes in the hypertrophic heart of CKD model rats
The mean mid-infrared spectra (900–1800 cm−1) of the myocardi-
um in non-AST-treated (CKD rats with hypertrophic heart) and sham-
control groups are shown in Fig. 2A. Difference spectrum generated by
the subtraction of spectrum of sham-control group from spectrum of
non-AST-treated group is shown in Fig. 2B. The absorption of amide I
(1651 cm−1) and amide II (1548 cm−1) was obviously increased in
the hypertrophic heart. Other protein bands were also conﬁrmed at
1245 (amide III), 1310, 1388 and 1446 cm−1, and these absorptions
were increased in hypertrophic hearts. FTIR spectroscopy has been
shown to be sensitive to the secondary structure of proteins. The ab-
sorption of amide I and other protein bands in hypertrophic hearts
were at the same position as in normal cardiac absorption in this
study. The FTIR absorbance band centered at 1338 cm−1 arises from
CH2 wagging vibration of proline side chains in some collagen typesmodel and sham-operated rats. No-AST, CKDmodel rats not treatedwith AST-120 (n=7);
weight. **P b0.01 vs. Sham. (B) Relative cross-sectional area of the heart in CKDmodel and
as a ratio relative to that of Sham. **P b0.01 vs. Sham. (C) Hematoxylin and eosin staining
ortion of myocardium in representative rats (non-AST-treated and sham-control groups).
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the extent of collagen in rat heart [25]. This absorption did not obviously
increase in non-AST-treated group compared to sham-control group.
In addition, the 1744 cm−1 band arose in hypertrophic hearts. This
band is due to the C_O stretching vibration of the ester group in part
of the lipids or triglycerides. The molecules forming the cell membrane
bilayer are phospholipids. The absorption between 985 and 1140 cm−1
are assigned to the v1, v3 phosphate vibration [26]. In the difference
spectrum (Fig. 2B), the absorption at 1744 cm−1 was stronger than
the absorption of phosphate vibration.
The total band intensities of each band corrected by cross-sectional
area of the heart are shown in Fig. 2C. The total band intensities of phos-
phate vibration and band associated with collagen did not have signiﬁ-
cant differences between non-AST-treated and sham-control groups,
but the total band intensities of amide I and lipid esterwere signiﬁcantly
increased in non-AST-treated group compared to sham-control group.
The FTIR images of amide I (1651 cm−1) and lipid-ester/protein dis-
tribution (1744/1651 cm−1) in non-AST-treated and sham-control rats
are shown in Fig. 2D. The amide I signal increased in the central portionFig. 2. Fourier transform infrared (FTIR) spectroscopic analyses of hypertrophic heart in chron
treated and sham-control groups. Non-AST-treated (n = 7); sham-control (n = 3). (B) Diffe
group. Non-AST-treated (n = 7, black line); sham-control (n = 3, gray line). (C) Total band in
and collagen (1338 cm−1) in hearts. These values are ratio band intensities corrected by the l
control, n = 3. Ratio of band intensity = Total band intensity in each heart divided by the me
FTIR images of the hearts showing the distribution of amide I (1651 cm−1) and lipid-ester
weight/body weight; 1.7-fold vs. sham-control) and sham-control groups. The band intensitie
rats were the same rats used in Fig. 1(C).of the myocardium in non-AST-treated rat, but such increase was not
seen in sham-control rat. The lipid-ester/protein signal was stronger
in non-AST-treated rat than in sham-control rat.
3.3. Animal characteristics and biochemical measurements among CKD
model groups
At 18 weeks of age, body weight, SBP and biochemical data did not
differ signiﬁcantly among CKD model groups (non-AST-treated; n =
7, AST-low group; n = 8, AST-high group; n = 6) (Table 2).
The physical characteristics and biochemical data of CKDmodel rats
at 26 weeks are shown in Table 3. Body weights and food intakes were
similar in all groups. Kidney function parameters (CCr, serum Cr, BUN
and urinary protein), blood pressure (SBP, DBP and HR), hemoglobin
level, mineral metabolic parameters, lipid parameters and oxidative
stress had no signiﬁcant differences among CKD model groups. In
serum levels of uremic toxins, PCS and HA did not differ signiﬁcantly
among three groups, but IS was signiﬁcantly decreased in AST-high
group compared to non-AST-treated group.ic kidney disease model rats. (A) Mean mid-infrared spectra of myocardium in non-AST-
rence spectrum generated by subtraction of sham-control group from non-AST-treated
tensities of amide I (1651 cm−1), phosphate (985–1140 cm−1), lipid ester (1744 cm−1)
evels of cross-sectional area of the heart. No-AST, Non-AST-treated, n = 7; Sham, sham-
an total band intensity in sham-control group. **P b 0.01, *P b 0.05; vs. sham-control. (D)
(1744 cm−1)/amide I band intensities in representative rats of non-AST-treated (heart
s are depicted in color as illustrated by the adjacent color-bar scale. These representative
Fig. 2 (continued).
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differences among CKDmodel groups (Fig. 3A and B). The doses of AST-
120 taken by individual rats at 25–26 weeks varied to some extent in
AST-treated groups. The relations between heart weight and AST-120
doses in AST-treated groups are shown in Fig. 3C. A strong negative cor-
relation was observed in AST-low group (r=−0.805, P b 0.05) as well
as in AST-high group (r=−0.893, P b 0.05).
Cardiac function, which was expressed as rate pressure product
(SBP × HR), had a positive correlation with heart weight (r =0.773,
P b 0.01), but not signiﬁcantly decreased in AST-treated groups com-
pared to non-AST-treated group (Fig. 3D).
As shown in Table 3, heart weight correlated positively with SBP,
DBP, urinary protein, serum levels of Cr, BUN, IS, PCS, HA, Pi, PTH,
FGF23, T-Cho, TG, and H-FABP and oxidative stress, and correlated neg-
atively with CCr. Serum levels of Cr, IS, PCS, HA and PTH also had nega-
tive correlations with AST-120 doses in both of AST-treated groups.
3.4. Morphologic changes in the myocardium of CKD rats
Fig. 4 shows the HE andMT stained sections of the central portion of
the myocardium of representative CKD model rats. The representativeTable 2
Animal characteristics at 18 weeks of age in chronic kidney disease model rats.
Non-AST-treated (n = 7)
Body weight, g 473.4 ± 20.2
Systolic blood pressure, mm Hg 147.8 ± 9.9
Creatinine clearance, mL/min 1.62 ± 0.16
Serum creatinine, mg/dL 0.77 ± 0.09
Blood urea nitrogen, mg/dL 55.9 ± 4.8
Urinary protein, mg/day 53.5 ± 23.8
Hemoglobin, g/dL 14.5 ± 0.7
Total cholesterol, mg/dL 66.9 ± 9.8
Triglycerides, mg/dL 161.6 ± 40.4
Inorganic phosphorus, mg/dL 6.49 ± 0.45rats of the CKD groups had serum Cr levels of approximately 1 mg/dL,
and similar body weight, serum Pi and PTH, and SBP levels at
26 weeks of age. In HE-stained sections, the width of myocardial ﬁ-
bers increased approximately 2-fold in non-AST-treated (heart
weight: 1.7-fold) and AST-low (heart weight: 1.7-fold vs. sham-
control) rats compared to AST-high rat (heart weight: 1.1-fold vs.
sham-control). In MT-stained sections, myocardial ﬁbrosis was
not obvious in all representative CKD model rats.
3.5. Chemical changes in the heart which is not hypertrophied
The mean mid-infrared spectra in AST-high (CKD model rats with-
out hypertrophic heart, n = 6) and non-AST-treated (CKD model rats
with hypertrophic heart, n= 7) groups are shown in Fig. 5A. Difference
spectrum generated by the subtraction of spectrum of AST-high group
from spectrum of non-AST-treated group is shown in Fig. 5B. AST-120
is an oral charcoal adsorbent, and adsorbs small- and middle-sized hy-
drophobic molecules in the gastrointestinal tract and is excreted into
the feces [27]. Thus, there is not AST-120 in itself to the heart. The ab-
sorptions of amide I (1651 cm−1) and amide II (1547 cm−1) were obvi-
ously decreased inAST-high group compared to non-AST-treated group.AST-treated
AST-low (n = 8) AST-high (n = 6)
470.0 ± 31.2 466.5 ± 5.6
145.2 ± 11.6 142.1 ± 4.5
1.59 ± 0.31 1.78 ± 0.23
0.80 ± 0.09 0.74 ± 0.11
59.2 ± 8.1 54.6 ± 5.8
64.0 ± 26.2 51.9 ± 20.1
14.6 ± 0.5 14.5 ± 0.6
72.0 ± 13.2 70.3 ± 11.1
159.4 ± 47.1 145.7 ± 25.4
6.36 ± 0.44 6.53 ± 0.56
Table 3
Animal characteristics in chronic kidney disease model rats with AST-120 at 26 weeks of age.
Non-AST-treated (n = 7) AST-treated With heart weight/BW Correlation with
AST-120 doses
AST-low AST-high
(n = 8) (n = 6) AST-low AST-high
Body weight (BW), g 532.7 ± 24.7 504.9 ± 64.9 495.9 ± 50.4 – NS NS
Mean food intake, g/day 21.2 ± 3.0 21.0 ± 4.3 21.5 ± 4.5 NS – –
Systolic blood pressure, mm Hg 174.5 ± 32.8 160.2 ± 26.8 162.6 ± 29.2 0.673†† NS −0.865†
Diastolic blood pressure, mm Hg 118.0 ± 19.4 121.3 ± 23.2 122.6 ± 19.4 0.730†† −0.742† NS
Heart rate, bpm 323.1 ± 26.5 323.0 ± 14.3 333.6 ± 27.6 NS NS NS
Hemoglobin, g/dL 13.4 ± 0.9 13.2 ± 0.7 12.7 ± 1.3 NS NS NS
Creatinine clearance (CCr), mL/min 1.28 ± 0.53 1.18 ± 0.67 1.29 ± 1.05 −0.804†† 0.723† NS
Serum creatinine, mg/dL 1.34 ± 0.65 1.45 ± 0.76 1.69 ± 1.22 0.753†† −0.832† −0.916†
Blood urea nitrogen, mg/dL 72.3 ± 17.5 81.6 ± 32.7 104.9 ± 65.2 0.701†† NS −0.942††
Urinary protein, mg/day 229.3 ± 118.0 275.1 ± 146.0 231.7 ± 157.4 0.674†† NS NS
Indoxyl sulfate, mg/dL 0.60 ± 0.24 0.37 ± 0.21 0.23 ± 0.18# 0.530† −0.724† −0.967††
p-Cresyl sulfate, μg/dL 6.43 ± 3.60 5.63 ± 5.01 3.33 ± 4.18 0.770†† −0.898†† −0.922††
Hippuric acid, mg/dL 0.78 ± 0.33 0.63 ± 0.33 0.48 ± 0.41 0.754†† −0.749† −0.957††
Inorganic phosphorus, mg/dL 6.26 ± 0.79 7.16 ± 1.66 7.78 ± 2.31 0.699†† NS −0.924††
Parathyroid hormone, pg/mL 2077.7 ± 1942.6 2975.3 ± 2823.0 3726.8 ± 3489.3 0.763†† −0.834† −0.901†
Fibroblast growth factor 23, pg/mL 2348.7 ± 2877.7 27,694.2 ± 71,180.4 34,777.6 ± 68,967.9 0.571†† NS NS
Total cholesterol, mg/dL 119.9 ± 27.8 151.0 ± 58.8 139.7 ± 67.4 0.810†† −0.780† NS
Triglycerides, mg/dL 254.0 ± 65.2 306.9 ± 100.4 236.8 ± 110.3 0.524† NS −0.860†
Heart-type fatty acid binding protein, ng/mL 0.87 ± 0.31 1.27 ± 1.30 0.70 ± 0.48 0.518† NS −0.828†
8-OHdG (ng/day) correlated by CCr (mL/min) 216.8 ± 136.2 174.1 ± 111.8 292.6 ± 277.3 0.565†† NS −0.958††
NS; not signiﬁcant difference.
8-OHdG; 8-hydroxydeoxyguanosine, #P b 0.05; vs. Non-AST-treated. ††P b 0.01, †P b 0.05; vs. Heart weight/100 g BW or vs. AST-120 doses.
Fig. 3. Cardiac hypertrophy in AST-treated chronic kidney disease (CKD) rats. Heart weight (A) and relative cross-sectional area of the heart (B) in CKDmodel rats. No-AST (●), non-AST-
treated, n= 7; AST-L ( ), AST-low, n= 8; AST-H ( ), AST-high, n= 6.Means± SD are depicted in the bar next to individual values. (C) Relationship between heart weight and dose of
AST-120 at 25–26 weeks in AST-low ( ) and AST-high ( ) groups. AST-low, n= 8; AST-high, n= 6. Correlation between heart weight and dosage of AST-120: at r=−0.805, P b 0.05 in
AST-lowgroup, and r=−0.893, P b 0.05 inAST-high group. Dark dotted line indicates themean heartweight of sham-control group, and light dotted line indicates themean heartweight
of non-AST-treated group. (D) Correlation between heart weight and rate pressure product at 26 weeks in non-AST-treated (●), AST-low ( ), AST-high ( ) and sham-control (○) groups
(r= 0.773, P b 0.01). Non-AST-treated, n = 7; AST-low, n = 8; AST-high, n = 6; sham-control, n = 6.
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Fig. 4.Hematoxylin and eosin staining (HE, upper) and Masson's trichrome staining (MT, lower) (magniﬁcation: ×40) of the central portion of myocardium in representative rats (non-
AST-treated, AST-low and AST-high groups).
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1447 cm−1, and these absorptions were decreased in non-
hypertrophic heart. The absorption at 1744 cm−1 was detected in
AST-high group, and decreased compared to non-AST-treated group.
The absorption of collagen at 1338 cm−1 in AST-high group was the
same as that in non-AST-treated group. Difference of v1, v3 phosphate
vibration was not clearly detected between AST-high and non-AST-
treated groups.
The total band intensities of each band corrected by cross-sectional
area of the heart are shown in Fig. 5C. The total band intensities of
amide I, phosphate vibration and the 1338 cm−1 band did not have sig-
niﬁcant differences between AST-high and non-AST-treated groups, but
lipid ester was signiﬁcantly decreased in AST-high group compared to
non-AST-treated group.
The FTIR images of amide I (1651 cm−1) and lipid-ester/protein dis-
tribution (1744/1651 cm−1) in AST-high rat are shown in Fig. 5D. The
increase of amide I signal in the center portion of the myocardium,
which was seen in non-AST-treated rat, was not conﬁrmed in AST-
high rat. The lipid-ester/protein distribution was weaker in AST-high
rat than in non-AST-treated rat.
3.6. The condition of thoracic aortas in CKD model rats
Calciﬁcation of thoracic aortas is associatedwith coronary and valvu-
lar calciﬁcations, reﬂecting an underlying atherosclerotic process [28].
These calciﬁcations have a possibility to associate with increasing cardi-
ac work, promoting heart failure, left ventricular hypertrophy and dia-
stolic dysfunction. Representative mid-infrared spectra of the thoracic
aortas in CKD model and sham-control rats are shown in Fig. 6A.
There were no obvious differences among four rats. FTIR images of the
thoracic aortas had no remarkable differences in phosphate/protein dis-
tribution among four rats (Fig. 6B). No deﬁnitive differences were de-
tected among all rats by HE staining (data not shown).
3.7. Serum levels of uremic toxins in CKD model and sham-control rats
Uremic toxins are normally excreted by the kidney and interact neg-
ativelywith biologic functions. A large number of uremic toxins are pro-
duced by colonmicrobes, andmay contribute to uremic toxicity [29,30].
AST-120 is known to adsorb these uremic toxins efﬁciently [31]. The
present study showed that serum levels of IS, PCS and HA were de-
creased in AST-treated groups compared to non-AST-treated group,
and have correlation with heart weight and AST-120 doses (Table 3).
The dosage of AST-120 was uneven in AST-high group at 7–8 weeks
after AST-120 administration (Fig. 7A). During experiment period,
serum levels of IS, PCS and HA were decreased signiﬁcantly in AST-low and AST-high groups compared to non-AST-treated group at
4 weeks after starting AST-120 treatment. However, serum IS level
was signiﬁcantly decreased only in AST-high group and serum levels
of PCS and HA were not signiﬁcantly decreased in AST-treated groups
at 8 weeks (Fig. 7B). As shown in Fig. 7C, the heart of AST-high rats, in
which levels of serum uremic toxins were similar to those of sham-
controls, was not hypertrophied.
4. Discussion
Our study demonstrated the presence of cardiac hypertrophy in 4/5
nephrectomized rats even though myocardial ﬁbrosis was not clearly
detected. The infrared spectrum of cardiac and vascular calciﬁcation
gave absorption peaks corresponding to vibration modes of phosphate
[32]. The mid-infrared spectra of heart and thoracic aortas did not
have obvious differences in phosphate absorption between CKD model
and sham-control rats, suggesting that vascular calciﬁcations were not
formed in CKD model rats of this study.
It is themost characteristic in the hypertrophic heart associatedwith
CKD that infrared signal derived from protein was stronger in the cen-
tral portion of myocardium of hypertrophic heart than that in the
same portion of normal heart (Fig. 2). Cardiac remodeling is accompa-
nied by increases in protein synthesis, and wall thickness changes to
minimize variability [33,34]. Amide I band of protein has been reported
to shift in infarcted heart tissue compared to control tissue [35]. This
shift indicated either a structural rearrangement of the existing tissue
or the expression of new proteins with different structural characteris-
tics. This study showed that amide I and other protein bands were not
seen to shift in CKDmodel rats compared to sham-control rats, suggest-
ing the amount of the same protein increased in hypertrophic heart tis-
sue. From the results of total band intensity of amide I (Fig. 2C) and
distribution (Fig. 2D), the amount of protein per cross-sectional area in-
creased, and proteins increased in the center portion ofmyocardiumbe-
fore ﬁbrosis was formed. This chronic increase may lead to myocardial
ﬁbrosis. In addition, the absorption at 1744 cm−1 was stronger than
the absorption of phosphate vibration, suggesting that lipids except
phospholipid tended to be increased in hypertrophic heart. Ectopic
lipid deposition in the heart has been reported in the uninephrectomized
rats [36]. Oxidative stress was signiﬁcantly increased in CKD model
rats (Tables 1 and 3), and may lead to the formation of oxidized lipids
in cell membranes [37]. The lipid deposition might be lipid peroxide.
However, this study was not able to examine it because only lipid
ester parts were detected by mid-infrared spectra.
On the other hand, the absorption of band associated with protein
was decreased in themyocardium of non-hypertrophic heart compared
to hypertrophic heart in CKD model rats. The absorption of lipid ester
1440 M. Kuwahara et al. / Biochimica et Biophysica Acta 1842 (2014) 1433–1443was also decreased in non-hypertrophic heart associated with CKD. It is
thought to be important for suppression of cardiac hypertrophy in
CKD that protein and lipid accumulation are not increased in the
myocardium.
The triggers of cardiac hypertrophy induce intercellular signaling
cascades that promote protein synthesis and protein stability [33]. The
present study showed that serum levels of Cr, PTH and colon-derived
uremic toxins (IS, PCS and HA) are associated with cardiac hypertrophy
and AST-120 doses. These compounds are classiﬁed as uremic toxins
[30,38]. A previous study suggests that uremic compounds in blood
might reduce inotropy in cultured heart cells and induce arrhythmias,
and showed that Cr led to the development of severe arrhythmia joined
by impaired contractility [39]. In these parameters, serum levels of IS,
PCS and HA may be directly reduced by AST-120 because only these
levels were decreased in AST-treated rats compared to non-AST-
treated rats. A recent study found that ISmay be associatedwith cardiac
remodeling mediated via activation of p38, p42/44 mitogen-activated
protein kinase and nuclear factor-kappa B pathways and has pro-Fig. 5. Fourier transform infrared (FTIR) spectroscopic analyses of non-hypertrophic heart in chron
non-AST-treated groups. AST-high (n= 6, black line); non-AST-treated (n= 7, gray line). (B) Di
AST-high (n = 6); non-AST-treated (n = 7). (C) Total band intensities of amide I (1651 cm−1),
These values are ratio band intensities corrected by the levels of cross-sectional area of the heart
band intensity in each heart divided by the mean total band intensity in sham-control group.
amide I (1651 cm−1) and lipid-ester (1744 cm−1)/amide I band intensities in representative ra
BW; 1.7-fold vs. sham-control). The band intensities are depicted in color as illustrated by the adﬁbrotic, pro-hypertrophic and pro-inﬂammatory effects on cardiac
cells [40]. This research suggests that ISmay contribute to direct adverse
cardiac effects in cell culture at a clinically relevant concentration range.
Effects of HA on the heart remain unknown, but in vitro study showed
that PCS increases collagen synthesis in cardiac ﬁbrosis and enhances
protein synthesis in cardiac myocytes [41]. In this study, Fig. 7B and C
suggest a possibility that suppression of hypertrophy in the heart
needs reducing the levels of not a speciﬁc uremic toxin but various ure-
mic toxins. These data also show the necessity tomaintain serum levels
of uremic toxins at the same level of normal condition constantly to sup-
press cardiac hypertrophy with CKD.
Uremic toxins induce the production of reactive oxygen species,
which produces oxidative stress, in in vivo studies [42]. Oxidative stress
induced by acute ischemia is reported to be involved with the progres-
sion of the disease into heart failure, causing ﬁbrosis, left ventricular
dysfunction and hypertrophy [37]. The present study showed that
oxidative stress was increased in CKD model rats, but decreased
in AST-low rats which hearts were hypertrophied compared toic kidney diseasemodel rats. (A)Meanmid-infrared spectra ofmyocardium in AST-high and
fference spectrum generated by subtraction of AST-high group from non-AST-treated group.
phosphate (985–1140 cm−1), lipid ester (1744 cm−1) and collagen (1338 cm−1) in hearts.
. AST-H, AST-high, n = 6; No-AST, non-AST-treated, n = 7. Ratio of band intensity = Total
#P b 0.05; vs. non-AST-treated. (C) FTIR images of the hearts showing the distribution of
ts of AST-high [heart weight/body weight (HW/BW); 1.1-fold] and non-AST-treated (HW/
jacent color-bar scale. These representative rats were the same rats used in Fig. 4.
Fig. 5 (continued).
Fig. 6. Spectroscopic analyses of thoracic aortas in representative rats (non-AST-treated, AST-low, AST-high and sham-control groups). These representative ratswere the same rats used in
Figs. 1(B) and 4. (A) Typical mid-infrared spectra of myocardium in representative rats. Typical peak of phosphate (hydroxyapatite) is at 985–1140 cm−1. (B) Portions of FTIR images of
thoracic aortas showing the distribution of phosphate/amide I (1650 cm−1) band intensities in representative rats.
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duced by uremic toxins may play an important role in the develop-
ment of cardiac abnormality, but hypertrophy is not induced only
by oxidative stress.
Several studies suggest that a forced reduction in cardiac utiliza-
tion of fatty acids may trigger the cardiac hypertrophic problem [43].
The H-FABP is involved in fatty acid metabolism by directly mediat-
ing transport of long-chain fatty acids in cardiomyocytes, and is
released into the bloodstream after myocardial damage [44]. In this
study, serum H-FABP level was signiﬁcantly increased in CKD, but
did not have signiﬁcant differences among CKD model rats, suggesting
thatmyocardial lipid accumulationmay not be amajor factor associated
with hypertrophy in this condition. Previous study proposed thatFig. 7. Serum levels of colon-derived uremic toxins in non-AST-treated (●, n = 7), AST-lo
doses of AST-120 in AST-treated rats. (B) Changes in serum levels of indoxyl sulfate (IS, lef
sham-control. ##P b 0.01; vs non-AST-treated. $P b 0.05; vs AST-low. (C) Correlation betwe
HA level of sham-control group. Correlation between heart weight and serum levels of HAlipid accumulation in failing myocardium has a possibility to increase
the levels of toxic intermediates leading to lipotoxicity and the amount
and composition of lipids in the myocardium contributes to the
development of cardiac dysfunction [45]. It is surely important that
the lipid load in the myocardium is reduced to ameliorate cardiac
abnormalities.
In conclusion, the present study found that the increase of protein
and lipid in myocardium was associated with cardiac remodeling in
CKD model rats. It suggests a possibility that high serum levels of
some uremic toxins and lipid accumulation in myocardium might be
involved in mechanisms of cardiac remodeling at the stage of moder-
ate renal dysfunction before vascular calciﬁcation and myocardial ﬁ-
brosis are established. Cardiac remodeling is essentially a protectivew ( , n = 8), AST-high ( , n = 6) and sham-control (○, n = 6) rats. (A) Changes in
t), p-cresyl sulfate (PCS, middle) and hippuric acid (HA, right). **P b 0.01, *P b 0.05; vs
en AST-120 doses and serum levels of HA (left). Dotted line indicates the mean serum
(right, r = 0.829, P b 0.01).
1443M. Kuwahara et al. / Biochimica et Biophysica Acta 1842 (2014) 1433–1443mechanism. The indirect control is necessary for the management of
cardiac remodeling associated with CKD.
Conﬂict of interest statement
The authors declare that there is no conﬂict of interest.
Acknowledgement
The authors are grateful to Hisamitsu Tanaka for advice on cardiac
pathology, and Akihiro Ohnishi and Hiromi Kimura-Suda for technical
support in FTIR analysis. We thank Kaori Kikuchi for assistance with
LC/ESI-MS/MS analysis.We also thankmembers of Adsorptivemedicine
and pharmacology section of Kureha Corporation for technical assis-
tance with animal surgery.
References
[1] A.S. Go, G.M. Chertow, D. Fan, C.E. McCulloch, C. Hsu, Chronic kidney disease and the
risks of death, cardiovascular events, and hospitalization, N. Engl. J. Med. 351 (2004)
1296–1305.
[2] R.J. Glassock, R. Pecoits-Filho, S.H. Barberato, Left ventricular mass in chronic kidney
disease and ESRD, Clin. J. Am. Soc. Nephrol. 4 (2009) S79–S91.
[3] J.N. Cohn, R. Ferrari, N. Sharpe, on behalf of an International Forum on Cardiac
Remodeling, Cardiac remodeling—concepts and clinical implications: a consensus
paper from an international forum on cardiac remodeling, J. Am. Coll. Cardiol. 35
(2000) 569–582.
[4] M.A. James, A.M. Saadeh, J.V. Jones, Wall stress and hypertension, J. Cardiovasc. Risk
7 (2000) 187–190.
[5] D. Levy, R.J. Garrison, D.D. Savage, W.B. Kannel, W.P. Castelli, Prognostic implications
of echocardiographically determined left ventricular mass in the Framingham heart
study, N. Engl. J. Med. 322 (1990) 1561–1566.
[6] P.N. Casale, R.B. Devereux, M. Milner, G. Zullo, G.A. Harshﬁeld, T.G. Pickering, J.H.
Laragh, Value of echocardiographic measurement of left ventricular mass in
predicting cardiovascular morbid events in hypertensive men, Ann. Intern. Med.
105 (1986) 173–178.
[7] M.J. Koren, R.B. Devereux, P.N. Casale, D.D. Savage, J.H. Laragh, Relation of left ven-
tricular mass and geometry to morbidity and mortality in uncomplicated essential
hypertension, Ann. Intern. Med. 114 (1991) 345–352.
[8] B.A. Vakili, P.M. Okin, R.B. Devereux, Prognostic implications of left ventricular hy-
pertrophy, Am. Heart J. 141 (2001) 334–341.
[9] L. Bolognese, P. Dellavesa, L. Rossi, G. Sarasso, A.S. Bongo, M. Scianaro, Prognostic
value of left ventricular mass in uncomplicated acute myocardial infarction and
one-vessel coronary artery disease, Am. J. Cardiol. 73 (1994) 1–5.
[10] K.T. Weber, Extracellular matrix remodeling in heart failure: a role for de novo an-
giotensin II generation, Circulation 96 (1997) 4065–4082.
[11] N. Koleganova, G. Piecha, E. Ritz, R. Bekeredjian, P. Schirmacher, C.P. Schmitt, M.L.
Gross, Interstitial ﬁbrosis and microvascular disease of the heart in uremia: amelio-
ration by a calcimimetic, Lab. Invest. 89 (2009) 520–530.
[12] V. Raizada, D. Hillerson, J.S. Amaram, B. Skipper, Angiotensin II-mediated left ven-
tricular abnormalities in chronic kidney disease, J. Investig. Med. 60 (2012)
785–791.
[13] C.D. Chue, N.C. Edwards, W.E. Moody, R.P. Steeds, J.N. Townend, C.J. Ferro, Serum
phosphate is associated with left ventricular mass in patients with chronic kidney
disease: a cardiac magnetic resonance study, Heart 98 (2012) 219–224.
[14] M.R. Custodio, M.K. Koike, K.R. Neves, L.M. dos Reis, F.G. Graciolli, C.L. Neves, D.G.
Batista, A.O. Magalhaes, P. Hawlitschek, I.B. Oliveira, W.V. Dominguez, R.M.A.
Moyses, V. Jorgetti, Parathyroid hormone and phosphorus overload in uremia: im-
pact on cardiovascular system, Nephrol. Dial. Transplant. 27 (2012) 1437–1445.
[15] C. Faul, A.P. Amaral, B. Oskouei, M.C. Hu, A. Sloan, T. Isakova, O.M. Gutierrez, R.
Aguillon-Prada, J. Lincoln, J.M. Hare, P. Mundel, A. Morales, J. Scialla, M. Fischer, E.
Z. Soliman, J. Chen, A.S. Go, S.E. Rosas, L. Nessel, R.R. Townsend, H.I. Feldman, M.S.
J. Sutton, A. Ojo, C. Gadegbeku, G.S.D. Marco, S. Reuter, D. Kentrup, K. Tiemann, M.
Brand, J.A. Hill, O.W. Moe, M. Kuro-o, J.W. Kusek, M.G. Keane, M. Wolf, FGF23 in-
duces left ventricular hypertrophy, J. Clin. Invest. 121 (2011) 4393–4408.
[16] M. Suzuki, Y. Hada, M. Akaishi, M. Hiroe, K. Aonuma, Y. Tsubakihara, T. Akizawa, Ef-
fects of anemia correction by erythropoiesis-stimulating agents on cardiovascular
function in non-dialysis patients with chronic kidney disease, Int. Heart J. 53
(2012) 238–243.
[17] N. Toyran, P. Lasch, D. Naumann, B. Turan, F. Severcan, Early alterations inmyocardia
and vessels of the diabetic rat heart: an FTIR microspectroscopic study, Biochem. J.
397 (2006) 427–436.[18] T. Shoji, A.Wada, K. Inoue, D. Hayashi, K. Tomida, Y. Furumatsu, T. Kaneko, N. Okada,
Y. Fukuhara, E. Imai, Y. Tsubakihara, Prospective randomized study evaluating the
efﬁcacy of the spherical adsorptive carbon AST-120 in chronic kidney disease pa-
tients with moderate decrease in renal function, Nephron Clin. Pract. 105 (2007)
c99–c107.
[19] T. Akizawa, Y. Asano, S. Morita, T. Wakita, Y. Onishi, S. Fukuhara, F. Gejyo, S. Matsuo,
N. Yorioka, K. Kurokawa, on behalf of the CAP-KD Study Group, Effect of a carbona-
ceous oral adsorbent on the progression of CKD: a multicenter, randomized, con-
trolled trial, Am. J. Kidney Dis. 54 (2009) 459–467.
[20] H. Fujii, F. Nishijima, S. Goto, M. Sugano, H. Yamato, R. Kitazawa, S. Kitazawa, M.
Fukagawa, Oral charcoal adsorbent (AST-120) prevents progression of cardiac dam-
age in chronic kidney disease through suppression of oxidative stress, Nephrol. Dial.
Transplant. 24 (2009) 2089–2095.
[21] K. Nakai, H. Fujii, K. Kono, S. Goto, M. Fukagawa, S. Nishi, Effects of AST-120 on left
ventricular mass in predialysis patients, Am. J. Nephrol. 33 (2011) 218–223.
[22] S. Goto, K. Kitamura, K. Kono, K. Nakai, H. Fujii, S. Nishi, Association between AST-
120 and abdominal aortic calciﬁcation in predialysis patients with chronic kidney
disease, Clin. Exp. Nephrol. 17 (2013) 365–371.
[23] K. Kikuchi, Y. Itoh, R. Tateoka, A. Ezawa, K. Murakami, T. Niwa, Metabolomic search
for uremic toxins as indicators of the effect of an oral sorbent AST-120 by liquid
chromatography/tandem mass spectrometry, J. Chromatogr. B Analyt. Technol.
Biomed. Life Sci. 878 (2010) 2997–3002.
[24] H. Kasai, H. Hayami, Z. Yamaizumi, H. Saito, S. Nishimura, Detection and identiﬁca-
tion of mutagens and carcinogens as their adducts with guanosine derivatives,
Nucleic Acids Res. 12 (1984) 2127–2136.
[25] R. Cheheltani, J.M. Rosano, B. Wang, A.K. Sabri, N. Pleshko, M.F. Kiani, Fourier trans-
form infrared spectroscopic imaging of cardiac tissue to detect collagen deposition
after myocardial infarction, J. Biomed. Opt. 17 (2012) 056014.
[26] A.L. Boskey, R. Mendelsohn, Infrared spectroscopic characterization of mineralized
tissues, Vib. Spectrosc. 38 (2005) 107–114.
[27] T. Niwa, T. Yazawa, M. Ise, M. Sugano, T. Kodama, Y. Uehara, K. Maeda, Inhibitory ef-
fect of oral sorbent on accumulation of albumin-bound indoxyl-sulfate in serum of
experimental uremic rats, Nephron 57 (1991) 84–88.
[28] A. Eisen, A. Tenenbaum, N. Koren-Morag, D. Tanne, J. Shemesh, M. Imazio, E.Z. Fisman,
M.Motro, E. Schwammenthal, Y. Adler, Calciﬁcation of the thoracic aorta as detected by
spiral computed tomography among stable angina pectoris patients; association with
cardiovascular events and death, Circulation 118 (2008) 1328–1334.
[29] P. Evenepoel, B.K.I. Meijers, B.R.M. Bammens, K. Verbeke, Uremic toxins originating
from colonic microbial metabolism, Kidney Int. Suppl. 76 (2009) S12–S19.
[30] E. Schepers, G. Glorieux, R. Vanholder, The gut: the forgotten organ in uremia? Blood
Purif. 29 (2010) 130–136.
[31] S. Goto, K. Yoshiya, T. Kita, H. Fujii, N. Fukagawa, Uremic toxins and oral adsorbents,
Ther. Apher. Dial. 15 (2011) 132–134.
[32] S.R. Contiguglia, A.C. Alfrey, N.L. Miller, D.E. Runnells, R.Z. Le Geros, Nature of soft tis-
sue calciﬁcation in uremia, Kidney Int. 4 (1973) 229–235.
[33] J.A. Hill, E.N. Olson, Cardiac plasticity, N. Engl. J. Med. 358 (2008) 1370–1380.
[34] J.V. Jones, A.S. Seraﬁ, M.A. James, Wall stress and the heart, J. Cardiovasc. Risk 7
(2000) 159–161.
[35] K.Z. Liu, M. Jackson, M.G. Sowa, H. Ju, I.M.C. Dixon, H.H. Mantsch, Modiﬁcation of the
extracellular matrix following myocardial infarction monitored by FTIR spectrosco-
py, Biochim. Biophys. Acta 1315 (1996) 73–77.
[36] H.L. Zhao, Y. Sui, L. He, J. Guan, S.J. Xiao, D.R. Zhong, Q. Xu, S.E. Zeng, Lipid
partitioning after uninephrectomy, Acta Diabetol. 48 (2011) 317–328.
[37] R. Ferrari, L. Agnoletti, L. Comini, G. Gaia, T. Bachetti, A. Cargnoni, C. Ceconi, S.
Curello, O. Visioli, Oxidative stress during myocardial ischaemia and heart failure,
Eur. Heart J. 19 (1998) B2–B11.
[38] R. Vanholder, R. De Smet, G. Glorieux, A. Argiles, U. Baurmeister, P. Brunet, W. Clark,
G. Cohen, P.P. De Deyn, R. Deppisch, B. Descamps-Latscha, T. Henle, A. Jorres, H.D.
Lemke, Z.A. Massy, J. Passlick-Deetjen, M. Rodriguez, B. Stegmayr, P. Stenvinkel, C.
Tetta, C. Wanner, W. Zidek, European Uremic Toxin Work Group (EUTox), Review
on uremic toxins: classiﬁcation, concentration, and interindividual variability, Kid-
ney Int. 63 (2003) 1934–1943.
[39] D.Weisensee, I. Low-Friedrich, M. Riehle, J. Bereiter-Hahn, W. Schoeppe, In vitro ap-
proach to ‘uremic cardiomyopathy’, Nephron 65 (1993) 392–400.
[40] S. Lekawanvijit, A. Adrahtas, D.J. Kelly, A.R. Kompa, B.H. Wang, H. Krum, Does indox-
yl sulfate, a uraemic toxin, have direct effects on cardiac ﬁbroblasts and myocytes?
Eur. Heart J. 31 (2010) 1771–1779.
[41] S. Lekawanvijit, A.R. Kompa, B.H. Wang, D.J. Kelly, H. Krum, Cardiorenal syndrome:
the emerging role of protein-bound uremic toxins, Circ. Res. 111 (2012) 1470–1483.
[42] L. Dou, N. Jourde-Chiche, V. Faure, C. Cerini, Y. Berland, F. Dignat-George, P. Brunet,
The uremic solute indoxyl sulfate induces oxidative stress in endothelial cells, J.
Thromb. Haemost. 5 (2007) 1302–1308.
[43] P.M. Barger, D.P. Kelly, Fatty acid utilization in the hypertrophied and failing heart:
molecular regulatory mechanisms, Am. J. Med. Sci. 318 (1999) 36–42.
[44] B. Binas, H. Danneberg, J. McWhir, L. Mullins, A.J. Clark, Requirement for the heart-type
fatty acid binding protein in cardiac fatty acid utilization, FASEB J. 13 (1999) 805–821.
[45] P.C. Schulze, Myocardial lipid accumulation and lipotoxicity in heart failure, J. Lipid
Res. 50 (2009) 2314–2323.
